Your guide to starting RYBREVANT *FASPRO*™ or RYBREVANT®

What are RYBREVANT *FASPRO* (amivantamab and hyaluronidase-lpuj) and RYBREVANT (amivantamab-vmjw)?

RYBREVANT *FASPRO* and RYBREVANT are prescription medicines used to treat adults with non–small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and has certain abnormal epidermal growth factor receptor (EGFR) gene(s):

- in combination with LAZCLUZE (lazertinib), a prescription medicine, as a first-line treatment for NSCLC
- in combination with carboplatin and pemetrexed for NSCLC in people whose disease has worsened on or after treatment with an EGFR tyrosine kinase inhibitor (TKI)
- in combination with carboplatin and pemetrexed as a first-line treatment for NSCLC
- alone for the treatment of NSCLC in people whose disease has worsened on or after platinum-based chemotherapy.

Your healthcare provider will perform a test to make sure that RYBREVANT *FASPRO* or RYBREVANT is right for you.

It is not known if RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE are safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not take RYBREVANT *FASPRO* if you are allergic to hyaluronidase or any of the ingredients in RYBREVANT *FASPRO*.

Before you receive RYBREVANT *FASPRO*, RYBREVANT or LAZCLUZE, tell your healthcare provider (HCP) about all of your medical conditions, including if you:

- have a history of lung or breathing problems, other than cancer.
- are pregnant or plan to become pregnant. RYBREVANT *FASPRO*, RYBREVANT and LAZCLUZE can harm your unborn baby.

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL
RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL)
+
LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg

Table of Contents

About Lung Cancer and *EGFR* Mutations 3

RYBREVANT *FASPRO* Injections

How Treatment Is Given 5
Preparing for Treatment 6
Side Effects 7

RYBREVANT Infusions

How Treatment Is Given 9
Preparing for Treatment 10
Side Effects 11

Important Tips, Support, and Safety Information

Tips to Help Manage Your Treatment Experience 13
Support Communities 14
Support & Savings 15
Important Safety Information 16

RYBREVANT *FASPRO* or RYBREVANT can be given as a first treatment or a second treatment, alone or in combination with other medicines, depending on the type of *EGFR* mutation in non–small cell lung cancer (NSCLC).

RYBREVANT *FASPRO* is a subcutaneous (under the skin) injection given in the stomach area (abdomen) by your healthcare provider, and RYBREVANT is an infusion given into your vein (intravenous infusion).

EGFR, epidermal growth factor receptor.

IMPORTANT SAFETY INFORMATION (cont'd)

Females who are able to become pregnant:

- Your HCP should do a pregnancy test before you start treatment with RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE.
- If you are taking RYBREVANT *FASPRO* or RYBREVANT, use effective birth control (contraception) during treatment and for 3 months after your last dose. If you are taking LAZCLUZE, use effective birth control (contraception) during treatment and for 3 weeks after your last dose.

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL | RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg



About Lung Cancer and *EGFR* Mutations

Actor portrayals.

Lung cancer

Lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. As these cells grow, they form tumors. When cells from tumors spread to other parts of the body, it's called "advanced" or "metastatic" cancer.

Non–small cell lung cancer

The 2 most common types of lung cancer are non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

The difference between these types of lung cancer is how the cancer cells look under a microscope. There may be different treatments approved for use for each type.

Your doctor diagnosed you with NSCLC, the most common type of lung cancer that makes up about 85% of all cases.

Biomarker testing may help your doctor identify the appropriate treatment

A biomarker is any molecule that can help show when your body is working normally or abnormally. This includes mutations in certain cells associated with advanced NSCLC. A biomarker test identifies biomarkers by testing body tissue, blood, or other bodily fluids, and can help your doctor determine which treatment is best for you.

Testing showed that you have a certain *EGFR* mutation.

IMPORTANT SAFETY INFORMATION (cont'd)

- o Tell your HCP right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE.

Males who have female partners who are able to become pregnant:

- o You should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE.

- are breastfeeding or plan to breastfeed. It is not known if RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE pass into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of RYBREVANT *FASPRO* or RYBREVANT. Do not breastfeed during treatment and for 3 weeks after your last dose of LAZCLUZE.

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL | RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg



About Lung Cancer and *EGFR* Mutations (cont'd)

Actor portrayals.

EGFR mutations

EGFR is a protein found on both normal cells and cancer cells. It drives cells to survive and grow. *EGFR* mutations may cause cancer cells to overgrow and spread to other parts of the body.

EGFR exon 19 deletions/exon 21 L858R substitution mutations

There are 2 *EGFR* mutations that represent 80% to 90% of all *EGFR* mutations in NSCLC. These are called "exon 19 deletions" and "exon 21 L858R substitution mutations."

EGFR exon 20 insertion mutations

There are other, less common mutations. One kind of *EGFR* mutation is called an "exon 20 insertion" mutation. Exon 20 insertion mutations are the third most frequent *EGFR* mutation in NSCLC.

IMPORTANT SAFETY INFORMATION (cont'd)

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. LAZCLUZE may affect the way other medicines work, and other medicines may affect how LAZCLUZE works. You should not start or stop any medicine before you talk with your HCP that prescribed LAZCLUZE.

What should I avoid while receiving RYBREVANT *FASPRO*, RYBREVANT, and/or LAZCLUZE?

RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment. Wear protective clothing and use broad-spectrum sunscreen during treatment.

What are the possible side effects of RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE?

RYBREVANT *FASPRO*, RYBREVANT, and/or LAZCLUZE may cause serious side effects, including:

- **allergic and injection-related reactions.** Allergic and injection-related reactions are common with RYBREVANT *FASPRO* and can be severe or serious. Tell your HCP right away if you get any of the following symptoms during or after your injection: shortness of breath, fever, chills, flushing, chest discomfort, dizziness or lightheadedness, or vomiting.

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL | RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg

How Treatment Is Given

Actor portrayal.

RYBREVANT *FASPRO* is given as a rapid ~5-minute injection under the skin (subcutaneous) in the stomach area (abdomen)

- You will be given RYBREVANT *FASPRO* injections in the stomach area by your healthcare provider. Your care team will also give you additional medications and take time to make sure you're doing well before you leave your visit
- Your doctor will decide how many doses you will receive, the time between doses, and the appropriate dose of RYBREVANT *FASPRO* based on your body weight
- Your doctor will give you other medicines before your RYBREVANT *FASPRO* injection to help reduce the risk of side effects. These medicines will include allergy medicine, a fever reducer, and a steroid

RYBREVANT *FASPRO* injections may be given in combination with other medicines, depending on the type of *EGFR* mutation in NSCLC

For the first treatment of advanced NSCLC with *EGFR* mutations (exon 19 deletions or exon 21 L858R substitution mutations)

- RYBREVANT *FASPRO* is approved as an injection in combination with LAZCLUZE, a pill you can take once a day, on your own schedule. Take LAZCLUZE exactly how your doctor tells you to
  - On days you are receiving RYBREVANT *FASPRO*, take LAZCLUZE before receiving your injection
- When RYBREVANT *FASPRO* injections are given in combination with LAZCLUZE, your doctor will start you on a medicine to prevent blood clots for the first 4 months of treatment

For the second treatment of advanced NSCLC with *EGFR* mutations (exon 19 deletions or exon 21 L858R substitution mutations) and for the first treatment of advanced NSCLC with *EGFR* exon 20 insertion mutations

- RYBREVANT *FASPRO* is approved to be used with chemotherapy. Chemotherapy consists of carboplatin and pemetrexed, which are infusions given into your vein through an IV line (intravenous infusion)

IMPORTANT SAFETY INFORMATION (cont'd)

- **infusion-related reactions.** Infusion-related reactions are common with RYBREVANT but can be severe or serious and can include life-threatening (anaphylaxis) allergic reaction. Tell your HCP right away if you get any of the following symptoms during your infusion of RYBREVANT: shortness of breath, difficulty breathing, or wheezing, chest discomfort, swelling of your eyes, lips, or tongue, fever, chills, numbness of your tongue, lips, cheeks, or gums, flushing, skin rash, hives, or itching, nausea or vomiting, stomach cramps, lightheadedness, dizziness, or fainting, or headache.

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg

Preparing for Treatment

Actor portrayal.

Tips to help you prepare for your injection appointments

Drink plenty of water the day before and have a good breakfast on injection day.

Wear loose clothes for comfort and so your care team can easily reach the injection area of your body.

Pay close attention to how you feel during an injection, and make sure to let your care team know if you experience any discomfort. They know how to help.

If you have any other questions about your treatment, ask your care team

IMPORTANT SAFETY INFORMATION (cont'd)

- **lung problems.** RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE can cause lung problems that can lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your HCP right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
- **blood clot problems.** RYBREVANT *FASPRO* or RYBREVANT, when given in combination with LAZCLUZE, can cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that can lead to death. Your HCP may start you on medicine to prevent blood clots for the first 4 months of treatment. Tell your HCP right away if you get any signs and symptoms of blood clots, including swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.
- **skin problems.** RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE can cause severe rash, including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. Your HCP may start you on an antibiotic for the first 3 months of treatment followed by an antibiotic lotion for your scalp for the next 9 months. During treatment, you should apply a non-comedogenic (does not clog pores) skin moisturizer (ceramide-based or other types of moisturizers that provide long lasting skin hydration and does not include drying ingredients) on your face and whole body (except scalp) and wash your hands and feet every day with 4% chlorhexidine solution. Tell your HCP right away if you get any skin reactions. Your HCP may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment.

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg


Actor portrayal.

Side Effects

Your care team will continuously support you along your treatment journey. It's important to tell your care team about side effects right away, if you:

- First experience symptoms of side effects
- Feel that the side effects are affecting daily activities
- Have been treating side effects according to your doctor's instructions but they do not improve

To help manage reactions, your treatment team may adjust, pause, or stop your injections, or give you certain medicines.

RYBREVANT *FASPRO* may cause serious side effects, including:

Allergic and injection-related reactions

- Allergic and injection-related reactions are common with RYBREVANT *FASPRO* and can be severe or serious
- Tell your doctor right away if you experience shortness of breath, fever, chills, flushing, chest discomfort, dizziness or lightheadedness, or vomiting during or after your injection

Lung problems

- RYBREVANT *FASPRO* can cause lung problems that can lead to death. Symptoms of lung problems may be similar to those from your lung cancer
- Tell your doctor right away if you have any new or worsening symptoms of lung problems including shortness of breath, cough, or fever

Blood clots

- RYBREVANT *FASPRO*, when given together with LAZCLUZE, can cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that may lead to death
- Your doctor will start you on a medicine to prevent blood clots for the first 4 months of treatment
- Tell your doctor right away if you notice swelling, pain, or tenderness in the leg; sudden unexplained chest pain; or shortness of breath

Skin problems

- RYBREVANT *FASPRO* can cause severe rash; including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin
- Tell your doctor right away if you get any skin reactions; your doctor may treat you with medicine(s) or send you to see a skin specialist (dermatologist)
- Taking certain steps can help lower your risk of skin-related side effects. Learn about those steps in the **Tips to Help Manage Your Treatment Experience section on page 13**

There are things you can do that may lower the chances of certain side effects. See the "Tips to Manage Your Treatment Experience" section on page 13 for more information

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg


Actor portrayal.

Side Effects (cont'd)

Liver problems

- LAZCLUZE may cause severe liver problems
- Tell your doctor right away if you experience pain on the right side of the stomach (abdomen), dark or brown (tea-colored) urine, or yellowing of your skin or the white part of your eyes
- Your doctor will do blood tests to check your liver before you start and during treatment with LAZCLUZE

Eye problems

- RYBREVANT *FASPRO* can cause eye problems. Tell your doctor right away if you experience eye pain, inflammation of eyelids, dry eyes, eye redness, blurred vision, changes in vision, itchy eyes, excessive tearing, or sensitivity to light. If you experience eye problems, your doctor may send you to see an eye specialist (ophthalmologist)
- You should not use contact lenses until your eye symptoms are checked by a doctor

Harm to your unborn baby

RYBREVANT *FASPRO* + LAZCLUZE can harm your unborn baby. Tell your doctor if you become pregnant or think you might be pregnant.

- If you or your partner are able to become pregnant, you should both use effective birth control during treatment and for 3 months after your final dose of RYBREVANT *FASPRO*, and during treatment and for 3 weeks after your last dose of LAZCLUZE

Most common side effects of RYBREVANT *FASPRO* + LAZCLUZE:

- Rash
- Infected skin around the nail
- Muscle and joint pain
- Feeling very tired
- Sores in the mouth
- Swelling of hands, ankles, feet, face, or all of your body
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Decreased appetite
- Headache
- Changes in certain blood tests

The most common side effects of RYBREVANT infusions, which may be experienced with RYBREVANT *FASPRO* injections, are listed on page 12. Talk to your doctor about the possible side effects of your specific treatment.

There are things you can do that may lower the chances of certain side effects.
See the "Tips to Manage Your Treatment Experience" section on page 13 for more information

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg

Actor portrayal.

How Treatment Is Given

RYBREVANT is an infusion given into your vein through an IV line (intravenous infusion)

- You will receive RYBREVANT infusions at your doctor's office or an infusion center
- Your doctor will decide how many doses you will receive, the time between doses, and the appropriate dose of each RYBREVANT infusion based on your body weight
- Your doctor will give you other medicines before each infusion to help reduce the risk of side effects. These medicines will include allergy medicine, a fever reducer, and a steroid

RYBREVANT infusions may be given in combination with other medicines, depending on the type of *EGFR* mutation in NSCLC

For the first treatment of advanced NSCLC with *EGFR* mutations (exon 19 deletions or exon 21 L858R substitution mutations)

- RYBREVANT infusions are used in combination with **LAZCLUZE, a pill you can take once a day**, on your own schedule. Take LAZCLUZE exactly how your doctor tells you to
  - On days you are receiving RYBREVANT, take LAZCLUZE before receiving your infusion
- When RYBREVANT infusions are given in combination with LAZCLUZE, your doctor will start you on medicine to prevent blood clots for the first 4 months of treatment

For the second treatment of advanced NSCLC with *EGFR* mutations (exon 19 deletions or exon 21 L858R substitution mutations) and for the first treatment of advanced NSCLC with *EGFR* exon 20 insertion mutations

- RYBREVANT infusions are used with chemotherapy. Chemotherapy consists of carboplatin and pemetrexed, which are also infusions given into your vein through an IV line (intravenous infusion)

IMPORTANT SAFETY INFORMATION (cont'd)

- **liver problems.** LAZCLUZE may cause severe liver problems, including increased liver function tests. Your HCP will do blood tests to check your liver before you start and during treatment. Tell your HCP right away if you get any symptoms of liver problems, including pain on the right side of your stomach area (abdomen), dark or brown (tea colored) urine, or yellowing of your skin or the white part of your eyes.

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg



Preparing for Treatment

Actor portrayal.

Tips to help you prepare for your infusion appointments

Drink plenty of water the day before and have a good breakfast on infusion day.

Infusions can last several hours, so make sure you've set aside enough time for your appointment. Ask your care team about how long your infusion will be.

Ask the office if it's okay to **bring a drink and snack** with you in case you get hungry.

Consider setting up transportation to and from the infusion center. You will receive medicines before your infusion that can make you drowsy. If you need help setting up a ride, reach out to your family and friends.

Wear loose clothes for comfort and so your care team can easily reach the infusion area of your body.

Bring a pillow and blanket for extra comfort.

Bring a book, game, puzzle, music, or other entertainment to help pass the time.

Pay close attention to how you feel during an infusion, and make sure to let your care team know if you experience any discomfort. They know how to help.

If you have any other questions about your treatment, ask your care team

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg


Actor portrayal.

Side Effects

Your care team will continuously support you along your treatment journey. It's important to tell your care team about side effects right away, if you:

- First experience symptoms of side effects
- Feel that the side effects are affecting daily activities
- Have been treating side effects according to your doctor's instructions but they do not improve

To help manage reactions, your treatment team may adjust, pause, or stop your infusions, or give you certain medicines.

Possible serious side effects of RYBREVANT include:

Infusion-related reactions

- Infusion-related reactions are common but can be severe or serious and can include life-threatening allergic reaction (anaphylaxis)
- Tell your doctor right away if you experience shortness of breath, difficulty breathing, or wheezing; flushing; chest discomfort; skin rash, hives, or itching; swelling of your eyes, lips, or tongue; nausea or vomiting; fever; stomach cramps; chills; lightheadedness, dizziness, or fainting; numbness of the tongue, lips, cheeks, or gums; or headache

Lung problems

- RYBREVANT may cause lung problems that may lead to death. Symptoms of lung problems may be similar to those from your lung cancer
- Tell your doctor right away if you experience any new or worsening lung symptoms, including shortness of breath, cough, or fever

Blood clots

- When RYBREVANT infusions are given in combination with LAZCLUZE, blood clots are a serious but common side effect. This can occur in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that may lead to death
- Your doctor will start you on medicine to prevent blood clots for the first 4 months of treatment
- Tell your doctor right away if you notice swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath

Skin problems

- RYBREVANT can cause severe rash; including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin
- Tell your doctor right away if you get any skin reactions; your doctor may treat you with medicine(s) or send you to see a skin specialist (dermatologist)
- Taking certain steps can help lower your risk of skin-related side effects. Learn about those steps in the **Tips to Help Manage Your Treatment Experience section on page 13**

There are things you can do that may lower the chances of certain side effects.
See the "Tips to Manage Your Treatment Experience" section on page 13 for more information

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg


Actor portrayal.

Side Effects (cont'd)

Liver problems

- LAZCLUZE may cause severe liver problems
- Tell your doctor right away if you experience pain on the right side of the stomach (abdomen), dark or brown (tea-colored) urine, or yellowing of your skin or the white part of your eyes
- Your doctor will do blood tests to check your liver before you start and during treatment with LAZCLUZE

Eye problems

- Tell your doctor right away if you experience eye pain, blurred vision, inflammation of the eyelids, changes in vision, dry eyes, itchy eyes, eye redness, excessive tearing, or sensitivity to light. If you experience eye problems, your doctor may send you to see an eye specialist (ophthalmologist)
- You should not use contact lenses until your eye symptoms are checked by a doctor

Harm to your unborn baby

RYBREVANT + LAZCLUZE can harm your unborn baby. Tell your doctor if you become pregnant or think you might be pregnant.

- If you or your partner are able to become pregnant, you should both use effective birth control during treatment and for 3 months after your final dose of RYBREVANT, and during treatment and for 3 weeks after your last dose of LAZCLUZE

Most common side effects of RYBREVANT in combination with LAZCLUZE, in combination with chemotherapy, or used alone:

- Rash
- Infected skin around the nail
- Infusion-related reactions
- Muscle and joint pain
- Sores in the mouth
- Swelling of hands, ankles, feet, face, or all of your body
- Unusual feeling in the skin (such as tingling or crawling feeling)
- Feeling very tired
- Diarrhea
- Constipation
- COVID-19
- Dry skin
- Bleeding
- Decreased appetite
- Itchy skin
- Nausea
- Changes in certain blood tests
- Vomiting
- Shortness of breath
- Cough

Talk to your doctor about the possible side effects of your specific treatment.

There are things you can do that may lower the chances of certain side effects.
See the "Tips to Manage Your Treatment Experience" section on page 13 for more information

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg

Tips to Help Manage Your Treatment Experience

Actor portrayal.

These steps may lower the chances of skin-related side effects, such as rash or infected skin around the nail or other side effects. Talk to your doctor about what steps are right for you.

Daily, at-home care options to discuss with your care team

Mild, ceramide-based moisturizer (such as La Roche-Posay Lipikar or CeraVe*†): Use on your face and body (except scalp) at least once a day.

Limit direct exposure to sunlight: Wear protective clothing and broad-spectrum sunscreen with SPF ≥30.

Antiseptic cleanser (such as chlorhexidine 4%): Use to wash your hands and feet once a day.

- **Oral antibiotics** (for the first 3 months of treatment) followed by an **antibiotic lotion** for your scalp (for the next 9 months) may be prescribed to reduce risk of skin-related side effects
- **Medicine to lower your risk of blood clots** will be prescribed if you are given RYBREVANT *FASPRO* injections or RYBREVANT infusions in combination with LAZCLUZE

Make sure to tell your doctor about any other medicines you are taking. Consider using a pill box to help you organize your medicines.

*Talk to your doctor about what is right for you.
†All trademarks are property of their respective owners.

More tips to help throughout treatment

- Consider bathing/showering with warm or cool water (not hot water)
- Use mild soaps and shampoos for sensitive skin

- Use laundry detergents made for sensitive skin and without perfumes
- Wear soft, loose-fitting clothing
- Wear gloves during activities that could cause nail infection (for example, cleaning)

- Eat a balanced diet
- Talk to your doctor about activities that feel right for you
- Seek out support from your family, friends, care team, and/or support groups

Talk to your care team to understand if these tips are right for you.

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL
RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL)
+
LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg

Support Communities

Connecting with others during your treatment journey

Facing lung cancer comes with many challenges, such as discussing the disease and treatment. It can help to find support from other people who are going through similar experiences. There are many groups available to help support you.

LUNGevity

The largest national lung cancer-focused nonprofit, committed to changing the outcomes for people with lung cancer through research, education, and support.

Visit lungevity.org

GO2 for Lung Cancer

GO2 for Lung Cancer relentlessly confronts lung cancer on every front, every day, for everyone. Founded by patients and survivors, they are dedicated to increasing survival for those at risk, diagnosed, and living with lung cancer.

Visit go2.org

EGFR Resisters

A group of people living with or personally affected by *EGFR*+ lung cancer.

Visit egfrcancer.org

Exon 20 Group

People facing lung cancer, their families, and their caregivers are welcome to join this free group.

Visit exon20group.org

Lung Cancer Foundation of America

Their mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.

Visit lcfamerica.org

Discover more support communities at
RYBREVANT.com/community-support/facing-cancer-together

Please see Important Safety Information throughout and on pages 16-18.
Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL
RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL)
+ LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg

Support & Savings

Once you and your doctor have decided that a RYBREVANT *FASPRO*–based or RYBREVANT-based treatment is right for you, sign up for:

RYBREVANT with Me

Starting a new treatment can be overwhelming and you may still have questions

We are here to help.

- Free, 1-on-1 dedicated Care Navigator Support
- Cost support options regardless of your insurance type
- Additional resources and community connections

Sign up for personalized support throughout your treatment journey now:

Sign up for support
RYBREVANTwithMe.com/signup
OR
Call **833-JNJ-wMe1** (833-565-9631),
Monday through Friday, 8:00 AM–8:00 PM ET

The support and resources provided by RYBREVANT withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL | RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg

IMPORTANT SAFETY INFORMATION

What are RYBREVANT *FASPRO* (amivantamab and hyaluronidase-lpuj) and RYBREVANT (amivantamab-vmjw)?

RYBREVANT *FASPRO* and RYBREVANT are prescription medicines used to treat adults with non–small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and has certain abnormal epidermal growth factor receptor (EGFR) gene(s):

- in combination with LAZCLUZE (lazertinib), a prescription medicine, as a first-line treatment for NSCLC
- in combination with carboplatin and pemetrexed for NSCLC in people whose disease has worsened on or after treatment with an EGFR tyrosine kinase inhibitor (TKI)
- in combination with carboplatin and pemetrexed as a first-line treatment for NSCLC
- alone for the treatment of NSCLC in people whose disease has worsened on or after platinum-based chemotherapy.

Your healthcare provider will perform a test to make sure that RYBREVANT *FASPRO* or RYBREVANT is right for you.

It is not known if RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE are safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not take RYBREVANT *FASPRO* if you are allergic to hyaluronidase or any of the ingredients in RYBREVANT *FASPRO*.

Before you receive RYBREVANT *FASPRO*, RYBREVANT or LAZCLUZE, tell your healthcare provider (HCP) about all of your medical conditions, including if you:

- have a history of lung or breathing problems, other than cancer.
- are pregnant or plan to become pregnant. RYBREVANT F*ASPRO*, RYBREVANT and LAZCLUZE can harm your unborn baby.

  Females who are able to become pregnant:

  - o Your HCP should do a pregnancy test before you start treatment with RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE.
  - o If you are taking RYBREVANT *FASPRO* or RYBREVANT, use effective birth control (contraception) during treatment and for 3 months after your last dose. If you are taking LAZCLUZE, use effective birth control (contraception) during treatment and for 3 weeks after your last dose.
  - o Tell your HCP right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE.

  Males who have female partners who are able to become pregnant:

  - o You should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE.

- are breastfeeding or plan to breastfeed. It is not known if RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE pass into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of RYBREVANT *FASPRO* or RYBREVANT. Do not breastfeed during treatment and for 3 weeks after your last dose of LAZCLUZE.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. LAZCLUZE may affect the way other medicines work, and other medicines may affect how LAZCLUZE works. You should not start or stop any medicine before you talk with your HCP that prescribed LAZCLUZE.

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL | RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg

IMPORTANT SAFETY INFORMATION (cont'd)

What should I avoid while receiving RYBREVANT *FASPRO*, RYBREVANT, and/or LAZCLUZE?

RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment. Wear protective clothing and use broad-spectrum sunscreen during treatment.

What are the possible side effects of RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE?

RYBREVANT *FASPRO*, RYBREVANT, and/or LAZCLUZE may cause serious side effects, including:

- **allergic and injection-related reactions.** Allergic and injection-related reactions are common with RYBREVANT *FASPRO* and can be severe or serious. Tell your HCP right away if you get any of the following symptoms during or after your injection: shortness of breath, fever, chills, flushing, chest discomfort, dizziness or lightheadedness, or vomiting.
- **infusion-related reactions.** Infusion-related reactions are common with RYBREVANT but can be severe or serious and can include life-threatening (anaphylaxis) allergic reaction. Tell your HCP right away if you get any of the following symptoms during your infusion of RYBREVANT: shortness of breath, difficulty breathing, or wheezing, chest discomfort, swelling of your eyes, lips, or tongue, fever, chills, numbness of your tongue, lips, cheeks, or gums, flushing, skin rash, hives, or itching, nausea or vomiting, stomach cramps, lightheadedness, dizziness, or fainting, or headache.
- **lung problems.** RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE can cause lung problems that can lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your HCP right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
- **blood clot problems.** RYBREVANT *FASPRO* or RYBREVANT, when given in combination with LAZCLUZE, can cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that can lead to death. Your HCP may start you on medicine to prevent blood clots for the first 4 months of treatment. Tell your HCP right away if you get any signs and symptoms of blood clots, including swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.
- **skin problems.** RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE can cause severe rash, including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. Your HCP may start you on an antibiotic for the first 3 months of treatment followed by an antibiotic lotion for your scalp for the next 9 months. During treatment, you should apply a non-comedogenic (does not clog pores) skin moisturizer (ceramide-based or other types of moisturizers that provide long lasting skin hydration and does not include drying ingredients) on your face and whole body (except scalp) and wash your hands and feet every day with 4% chlorhexidine solution. Tell your HCP right away if you get any skin reactions. Your HCP may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment.
- **liver problems.** LAZCLUZE may cause severe liver problems, including increased liver function tests. Your HCP will do blood tests to check your liver before you start and during treatment. Tell your HCP right away if you get any symptoms of liver problems, including pain on the right side of your stomach area (abdomen), dark or brown (tea colored) urine, or yellowing of your skin or the white part of your eyes.
- **eye problems.** RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE can cause eye problems. Tell your HCP right away if you get symptoms of eye problems including eye pain, inflammation of eyelids, dry eyes, eye redness, blurred vision, changes in vision, itchy eyes,

IMPORTANT SAFETY INFORMATION (cont'd)

excessive tearing, and sensitivity to light. Your HCP may send you to see an eye specialist (ophthalmologist) if you get new or worsening eye problems during treatment. You should not use contact lenses until your eye symptoms are checked by an HCP.

The most common side effects of RYBREVANT *FASPRO* in combination with LAZCLUZE include: rash, infected skin around the nail, muscle and joint pain, feeling very tired, sores in the mouth, swelling of hands, ankles, feet, face, or all of your body, nausea, diarrhea, vomiting, constipation, decreased appetite, headache, and changes in certain blood tests.

The most common side effects seen with intravenous (IV) RYBREVANT, which may be experienced with RYBREVANT *FASPRO*, are listed below:

- **RYBREVANT in combination with LAZCLUZE:** rash, infected skin around the nail, infusion-related reaction, muscle and joint pain, sores in the mouth, swelling of hands, ankles, feet, face, or all of your body, unusual feeling in the skin (such as tingling or a crawling feeling), feeling very tired, diarrhea, constipation, COVID-19, bleeding, dry skin, decreased appetite, itchy skin, nausea, and changes in certain blood tests.
- **RYBREVANT in combination with carboplatin and pemetrexed:** rash, infected skin around the nail, infusion-related reaction, feeling very tired, nausea, sores in the mouth, constipation, swelling of hands, ankles, feet, face, or all of your body, decreased appetite, muscle and joint pain, vomiting, COVID-19, and changes in certain blood tests.
- **RYBREVANT given alone:** rash, infusion-related reaction, infected skin around the nail, muscle and joint pain, shortness of breath, nausea, swelling of hands, ankles, feet, face, or all of your body, cough, feeling very tired, sores in the mouth, constipation, vomiting, and changes in certain blood tests.

LAZCLUZE may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

Your HCP may temporarily stop, decrease your dose, or completely stop your treatment with RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE if you have serious side effects.

These are not all of the possible side effects of RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of RYBREVANT *FASPRO*, RYBREVANT, or LAZCLUZE:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use LAZCLUZE for a condition for which it was not prescribed. Do not give LAZCLUZE to other people, even if they have the same symptoms that you have. It may harm them.

Please read full Prescribing Information for RYBREVANT *FASPRO*, RYBREVANT, and LAZCLUZE.

cp-493867v3

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL | RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg

RYBREVANT Faspro™ (amivantamab and hyaluronidase-lpuj) Subcutaneous injection | 160 mg/2,000 units per mL | RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE® (lazertinib) Tablets | 240 mg/80 mg

Inside, you'll find helpful information about...

Lung Cancer and *EGFR* Mutations

How Treatment Is Given

Preparing for Treatment

Side Effects

Tips to Help Manage Your Treatment Experience

Support Communities

Support & Savings

Important Safety Information

Discover real stories from patients who have been prescribed a RYBREVANT-based or RYBREVANT *FASPRO*–based regimen at RYBREVANT.com/community-support/patient-stories

© Johnson & Johnson and its affiliates 2026 05/26 cp-511877v3

Johnson&Johnson